Target intelligence / Profile preview

Escherichia coli O-antigen (E. coli O-antigen)

Target
E. coli O-antigen
Molecular classification
Other (specifically, cell surface polysaccharide, not a protein, enzyme, receptor, or channel)
01

Overview

The **Escherichia coli O-antigen** is the highly variable polysaccharide component of the lipopolysaccharide (LPS) on the outer membrane of E. coli. It consists of repeating oligosaccharide units (commonly 2–7 sugar residues per repeat), covalently linked to the core oligosaccharide and lipid A. The structure and sequence of O-antigen repeats differ between E. coli serotypes and underpin the O serogrouping system used in epidemiology and diagnostics. O-antigens play a significant role in immune evasion, virulence, and survival in the host by masking the bacterium from the immune system and environmental threats. Their biosynthesis is determined by the chromosomal O-antigen gene clusters, which also explain the extensive diversity among strains. While not a single defined receptor or enzyme, the O-antigen is a critical epitope for serological detection and a focus for vaccine development against specific pathogenic E. coli strains.

Other names
O-specific polysaccharideO-polysaccharideO antigenO side chain of LPS (lipopolysaccharide)
02

Mechanism of action

For vaccines/antibodies: Induce immune response by generation of anti-O-antigen antibodies that opsonize bacteria or facilitate complement-mediated killing For antibiotics: Disrupt bacterial membrane integrity (polymyxins), but these target the entire LPS, not just the O-antigen portion

03

Biological functions

Immune evasion (shielding bacteria from host defenses such as complement and phagocytosis)Serotype determination (basis for E. coli serotyping and bacterial classification)Structural component of bacterial outer membrane (part of LPS)
04

Disease associations

Infection (major role in pathogenicity of E. coli, including diarrheal and extraintestinal diseases)Immune response (elicits strong antibody responses and acts as a key antigenic determinant)
05

Safety considerations

High antigenic diversity and variation across O-antigen types limit broad-spectrum vaccine/drug developmentCross-reactivity with human antigens rare but theoretically possiblePotential for immune evasion via O-antigen variation
06

Interacting drugs

Antibiotics and bactericidal agents that target LPS as a whole (e.g., polymyxins), though not specific to O-antigen itself

1 more in the full profile.

07

Biomarkers

Serotype-specific anti-O-antigen antibodies (used for epidemiology, typing, and diagnostic identification of E. coli strains)

Beyond the preview

Go deeper on Escherichia coli O-antigen (E. coli O-antigen).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Escherichia coli O-antigen (E. coli O-antigen).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call